Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice

Journal of Diabetes Investigation

Volumn 8, Issue 4, 2017, Pages 446-452

  Takei, Kenta ^a   Han, Song Iee ^a   Murayama, Yuki ^a   Satoh, Aoi ^a   Oikawa, Fusaka ^a   Ohno, Hiroshi ^a   Osaki, Yoshinori ^a   Matsuzaka, Takashi ^a   Sekiya, Motohiro ^a   Iwasaki, Hitoshi ^a   Yatoh, Shigeru ^a   Yahagi, Naoya ^a   Suzuki, Hiroaki ^a   Yamada, Nobuhiro ^a   Nakagawa, Yoshimi ^a   Shimano, Hitoshi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Lipid metabolism; Peroxisome proliferator activated receptor ; Selective peroxisome proliferator activated receptor modulator

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FENOFIBRATE; PEMAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; BENZOXAZOLE DERIVATIVE; BUTYRIC ACID DERIVATIVE; K-877 COMPOUND; PYRIMIDINE DERIVATIVE; X BOX BINDING PROTEIN 1; XBP1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FATTY ACID OXIDATION; GENE EXPRESSION REGULATION; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; LIPID METABOLISM; LIPID STORAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PPARA GENE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRIACYLGLYCEROL BLOOD LEVEL; AGONISTS; ANIMAL; C57BL MOUSE; CELL LINE; COMPARATIVE STUDY; DRUG EFFECTS; GENE EXPRESSION; LIVER; METABOLISM; PRECLINICAL STUDY;

ANIMALS; BENZOXAZOLES; BUTYRATES; CELL LINE; DRUG EVALUATION, PRECLINICAL; FENOFIBRATE; GENE EXPRESSION; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIVER; MALE; MICE, INBRED C57BL; PPAR ALPHA; PYRIMIDINES; X-BOX BINDING PROTEIN 1;

EID: 85018838086     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12621     Document Type: Article

References (17)

1. Ip E, Farrell GC, Robertson G, et al. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38: 123–132.
2. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905–910.
3. Bloomfield Rubins H, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001; 103: 2828–2833.
4. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med 1999; 341: 410–418.
5. Tanne D, Koren-Morag N, Graff E, et al. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 2001; 104: 2892–2897.
6. The Bezafibrate Infarction Prevention(BIP) Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102: 21–27.
7. Raza-Iqbal S, Tanaka T, Anai M, et al. Transcriptome Analysis of K-877 (a Novel Selective PPARalpha Modulator (SPPARMalpha))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver. J Atheroscler Thromb 2015; 22: 754–772.
8. Fruchart JC. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc Diabetol 2013; 12: 82.
9. Yamamoto T, Shimano H, Nakagawa Y, et al. SREBP-1 interacts with hepatocyte nuclear factor-4 alpha and interferes with PGC-1 recruitment to suppress hepatic gluconeogenic genes. J Biol Chem 2004; 279: 12027–12035.
10. Nakagawa Y, Shimano H, Yoshikawa T, et al. TFE3 transcriptionally activates hepatic IRS-2, participates in insulin signaling and ameliorates diabetes. Nat Med 2006; 12: 107–113.
11. Fujimoto Y, Nakagawa Y, Satoh A, et al. TFE3 controls lipid metabolism in adipose tissue of male mice by suppressing lipolysis and thermogenesis. Endocrinology 2013; 154: 3577–3588.
12. Hennuyer N, Duplan I, Paquet C, et al. The novel selective PPARalpha modulator (SPPARMalpha) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis 2016; 249: 200–208.
13. Badman MK, Pissios P, Kennedy AR, et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5: 426–437.
14. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5: 415–425.
15. Jha P, Claudel T, Baghdasaryan A, et al. Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. Hepatology 2014; 59: 858–869.
16. Chanda D, Lee CH, Kim YH, et al. Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology 2009; 50: 880–892.
17. Martinon F, Chen X, Lee AH, et al. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat Immunol 2010; 11: 411–418.